Literature DB >> 15687030

The efficacy of live tuberculosis vaccines after presensitization with Mycobacterium avium.

G W de Lisle1, B J Wards, B M Buddle, D M Collins.   

Abstract

The variable efficacy of BCG in humans has been extensively documented but its cause is still not well understood. One possible reason for this variation is the effect of presensitization with environmental mycobacteria. To investigate in guinea pigs the effects of presensitization with well characterized Mycobacterium avium strains on the vaccine efficacy of BCG and of two recently developed, avirulent strains of Mycobacterium bovis. Two strains of M. avium containing the DNA insertion element IS901 (M. avium+) and two strains not containing this element (M. avium-) were inoculated subcutaneously or by oral administration into guinea pigs to assess their virulence in these animals and their ability to induce delayed type hypersensitivity to tuberculins. Subsequently, groups of guinea pigs presensitized with orally administered M. avium+ and M. avium- and a control group were vaccinated with BCG, or one of two newly attenuated strains of M. bovis. All groups were then challenged by the aerosol route with virulent M. bovis. Vaccine efficacy was assessed 5 weeks later by the presence of macroscopic lesions and bacterial counts of spleen and lung. No macroscopic lesions were observed in any of the guinea pigs inoculated with strains of M. avium+ or M. avium- and all animals gave delayed-type hypersensitivity skin-test reactions to avian PPD. In the vaccine experiment, presensitization with orally administered M. avium+ alone produced a low level of protection against subsequent challenge with virulent M. bovis. In the absence of presensitization with M. avium or after presensitization with an M. avium- strain, BCG and two attenuated strains of M. bovis produced significant levels of protection. No additional protection was observed in lungs of guinea pigs presensitized with M. avium+ and subsequently vaccinated with BCG. In contrast, both newly attenuated strains of M. bovis induced significant protection in lungs after such presensitization. Presensitization of guinea pigs by the oral administration of M. avium+ provides a model for testing vaccines under conditions where the efficacy of BCG has been compromised by prior sensitization with environmental mycobacteria.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15687030     DOI: 10.1016/j.tube.2004.09.007

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  11 in total

Review 1.  Recombinant Mycobacterium bovis BCG as an HIV vaccine vector.

Authors:  Rosamund Chapman; Gerald Chege; Enid Shephard; Helen Stutz; Anna-Lise Williamson
Journal:  Curr HIV Res       Date:  2010-06       Impact factor: 1.581

2.  Environmental strains of Mycobacterium avium interfere with immune responses associated with Mycobacterium bovis BCG vaccination.

Authors:  Sarah L Young; Lynn Slobbe; Rachel Wilson; Bryce M Buddle; Geofferey W de Lisle; Glenn S Buchan
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

Review 3.  Nontuberculous Mycobacteria and Heterologous Immunity to Tuberculosis.

Authors:  Javeed A Shah; Cecilia S Lindestam Arlehamn; David J Horne; Alessandro Sette; Thomas R Hawn
Journal:  J Infect Dis       Date:  2019-08-30       Impact factor: 5.226

Review 4.  Vaccines for tuberculosis: novel concepts and recent progress.

Authors:  T Mark Doherty; Peter Andersen
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

Review 5.  Mycobacterium avium in the postgenomic era.

Authors:  Christine Y Turenne; Richard Wallace; Marcel A Behr
Journal:  Clin Microbiol Rev       Date:  2007-04       Impact factor: 26.132

6.  Mycobacterium avium subsp. paratuberculosis and M. avium subsp. avium are independently evolved pathogenic clones of a much broader group of M. avium organisms.

Authors:  Christine Y Turenne; Desmond M Collins; David C Alexander; Marcel A Behr
Journal:  J Bacteriol       Date:  2008-02-01       Impact factor: 3.490

7.  Recombinant Mycobacterium bovis bacillus Calmette-Guerin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites.

Authors:  Jae-Sung Yu; James W Peacock; William R Jacobs; Richard Frothingham; Norman L Letvin; Hua-Xin Liao; Barton F Haynes
Journal:  Clin Vaccine Immunol       Date:  2007-05-16

8.  Identification of antigens specific to non-tuberculous mycobacteria: the Mce family of proteins as a target of T cell immune responses.

Authors:  Anna M Checkley; David H Wyllie; Thomas J Scriba; Tanya Golubchik; Adrian V S Hill; Willem A Hanekom; Helen McShane
Journal:  PLoS One       Date:  2011-10-25       Impact factor: 3.240

9.  Immunogenicity of a recombinant Mycobacterium smegmatis vaccine expressing the fusion protein CMX in cattle from Goiás State, Brazil.

Authors:  Duanne Alves Da Silva; Marcos Antônio Rocha Cavalcanti; Fábio Muniz De Oliveira; Monalisa Martins Trentini; Ana Paula Junqueira-Kipnis; André Kipnis
Journal:  J Vet Med Sci       Date:  2014-03-31       Impact factor: 1.267

10.  Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis.

Authors:  Hazel C Poyntz; Elena Stylianou; Kristin L Griffiths; Leanne Marsay; Anna M Checkley; Helen McShane
Journal:  Tuberculosis (Edinb)       Date:  2014-01-02       Impact factor: 3.131

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.